Protein Tyrosine Phosphatases Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Protein Tyrosine Phosphatases (PTPs) are a  superfamily with the members being regulators in multiple signal transduction pathways. PTPs catalyze the dephosphorylation of Protein Tyrosine Kinase (PTK) themselves or their downstream targets. Therefore, Protein Tyrosine Phosphorylation is a critical regulatory process responsible for regulating cell proliferation, adhesion, communication, and differentiation. These have been categorized into four types depending upon the amino acid sequence and substrate specificity, namely classical phosphorylated tyrosine (pTyr)-specific PTPs, dual-specific phosphatases (DSPs), Cdc25 phosphatase, and low molecular weight PTPs (LMW-PTPs). Classical phosphorylated tyrosine (pTyr)-specific PTPs is further categorized into intracellular and receptor-type PTPs. Proper working of the immune response is essential else the body would become a hub of many diseases. PTP dysfunction would lead to a variety of diseases like various types of cancers, Type 2 Diabetes, and Autoimmune diseases like Rheumatoid Arthritis and so clinical investigations around the globe are being conducted to study the mechanism in detail and possible treatment that could be used in case of their dysfunction. Extensive research is being conducted globally to discover new and novel molecules to be used as Protein Tyrosine Phosphatase, like Suramin, is used for the treatment of African Sleeping Sickness. The development and launch of new products will thus increase the market’s revenue in the forecasted years. According to the WHO 2023 report, an estimated 700,000 to 1 million new cases are reported annually, with about 85% of all Cutaneous Leishmania occurring in America, the Mediterranean basin, the Middle East, and central Asia. Due to the poor hygienic conditions of these regions and the increasing prevalence of other indications, there is an excellent market for the global players ahead.

Several of these inhibitors are on the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 47 products in different stages of clinical trials - 3 in Phase 3, 12 in Phase 2, and 15 in Phase 1 of the clinical trials.

Drugs in the Pipeline of Protein Tyrosine Phosphatase

• Germanin (suramin)
• Lenocta (sodium stibogluconate)
• batoprotafib (TNO155)
• vociprotafib (RMC-4630)
• ISIS 113715
• Sulforadex (sulforafan alfadex)
• Ycanth (cantharidin)
• BBP-398
• ERAS-601
• JAB-3312
• trodulamine (MSI-1436)
• BR790
• JAB-3068
• NVG-291
• PRL3-Zumab
• RLY-1971
• BNT111
• ETS-001
• HBI-2376
• suramin
• ABBV-CLS-484
• ABBV-CLS-579
• BPI-442096
• ENT-03
• HS-10381
• ICP-189
• ISIS-PTP1BRx
• PF-07284892
• SH3809

Clinical Activity and Developments of Protein Tyrosine Phosphatase

As of July 2023, various companies have approximately 47 products for 137 diseases. For these diseases, many trials are being conducted by players globally. For instance,

• Rediscovery Life Sciences is conducting a Phase 2 clinical trial to study the effects of Suramin in subjects with Furosemide-Resistant Acute Kidney Injury that is expected to complete by December 2023.
• Intra-IMMUSG Pte Ltd is conducting a Phase 2 clinical trial to assess the safety and efficacy of PRL3-zumab in Solid Tumors that is expected to complete by December 2023.
• First Affiliated Hospital of Jinan University is conducting a Phase 2 clinical trial to evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with 65 p53 mutation from a defined list that is expected to complete by February 2024.